<DOC>
	<DOCNO>NCT01453257</DOCNO>
	<brief_summary>Treatment option patient colorectal cancer ( CRC ) increase last year . However , validate prospective molecular marker CRC select agent well treat individual case . The conventional first-line treatment CRC patient clinical study get proportion patient free progression 12 month range 35-40 % median 9 month free disease progression . The aim study demonstrate identification therapeutic target real time prospectively use customize treatment get proportion colorectal metastatic patient patient free progression disease 12 month 50 % .</brief_summary>
	<brief_title>Study Target-Guided Chemotherapy Metastatic Colorectal Patients</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Colorectal adenocarcinoma stage IV patient . ECOG= 01 Age &gt; 18 year . Fit receive chemotherapy treatment Availability tumor tissue possibility tumor biopsy determine therapeutic target . Adequate renal ( Cr &lt; 1,5 mg/d ) , liver ( bilirubin≤1,5 mg/dl , AST ALT ≤ 3.0 x upper limit normal ) normal bone marrow function ( absolute neutrophil count ≥ 1500/µl , hemoglobin ≥ 9.0g/dl platelet count ≥ 100.000/µl ) Contraindication administration drug use study include capecitabine , irinotecan , oxaliplatin , cetuximab bevacizumab . Previous Chemotherapy treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Molecular Targets</keyword>
	<keyword>Personalize Treatment</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Complete Response Rate</keyword>
</DOC>